Medical - Healthcare Plans · NYSE
Current Price
$80.84
Intrinsic Value
$115.21
+29.8% margin of safety
As of 2026-11-20, the base-case DCF model estimates the intrinsic value of CVS Health Corp. (CVS) at $115.21 per share, compared with a market price of $80.84, a margin of safety of +29.8%. The base case assumes 4.6% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $80.84 to $155.61. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
At $80.84, CVS trades about 29.8% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
↑Integrated Healthcare Ecosystem
CVS Health's unique integration of pharmacy, insurance (Aetna), and retail health services creates significant customer lock-in. This comprehensive offering makes it difficult for consumers to switch providers without losing benefits or convenience.
↑Scale and Data Advantage
The sheer scale of CVS's retail pharmacy footprint and Aetna's large member base generates vast amounts of health data. This data fuels personalized health services and operational efficiencies, creating a competitive edge.
↑Brand Trust and Recognition
CVS has built a strong, trusted brand over decades, particularly in the pharmacy sector. This established reputation fosters customer loyalty and reduces the perceived risk of choosing CVS for health needs.
INVESTMENT RISKS
↓Litigation and Shareholder Investigations
Ongoing investigations and potential litigation related to corporate governance and fiduciary duties can lead to significant legal costs and reputational damage. This distracts management and can impact investor confidence.
↓Execution Risk in Healthcare Transformation
While CVS is undergoing a turnaround, the complexity of integrating diverse healthcare services presents execution risks. Failure to effectively manage these integrations could hinder growth and profitability.
↓Macroeconomic Headwinds and Healthcare Affordability
Broader economic downturns and increasing healthcare costs for consumers can impact demand for CVS's services. Reduced affordability may lead to decreased prescription volumes and elective health service utilization.
Base case
Intrinsic Value
$115.21
Margin of safety
+29.8%
Expected annual return
+7.3%
Base case assumptions: 4.6% annual growth, 10.0% discount rate, 6.64x exit multiple, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for CVS Health Corp. respond.
Open DCF Calculator for CVSCVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.
Revenue/Share (TTM)
$328.09
FCF/Share (TTM)
$12.14
ROIC (TTM)
8.0%
ROE (TTM)
14.1%
P/FCF
6.6x
EV/EBITDA
8.5x
FCF Yield
15.05%
Debt/Equity
0.94x
Based on trailing twelve-month data, CVS shows a free cash flow per share of $12.14 and a ROIC of 8.0%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 6.6x and FCF yield of 15.05% are important context metrics when evaluating CVS's stock valuation relative to peers.
CVS Health Corp. currently generates $12.14 in free cash flow per share. At the current price of $80.84, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
CVS trades at a P/FCF ratio of 6.6x with a free cash flow yield of 15.05%. A low P/FCF means investors are paying less per dollar of free cash flow; whether that is cheap depends on the company's growth, cyclicality, and capital intensity. However, whether CVS is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
To perform a DCF valuation on CVS Health Corp.: (1) Start with the trailing free cash flow per share ($12.14) as the base, (2) project future FCF growth over 5-10 years based on Medical - Healthcare Plans industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting CVS's risk profile — with a debt-to-equity of 0.94x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For CVS Health Corp., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Healthcare Plans trends, then discounting those amounts to today's dollars. CVS's ROIC of 8.0% shows moderate capital returns.
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For CVS, with a debt-to-equity ratio of 0.94x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 8.5x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
DCF and P/E value CVS with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.